Esperion Therapeutics, Inc.
ESPR
$3.14
-$0.01-0.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 37.72% | 390.04% | -6.13% | 79.45% | -166.30% |
| Total Depreciation and Amortization | 3.85% | -3.70% | 0.00% | 170.00% | -- |
| Total Amortization of Deferred Charges | -15.74% | 272.67% | 89.49% | 85.52% | 59.95% |
| Total Other Non-Cash Items | -141.09% | -45.55% | -15.28% | -88.58% | -64.20% |
| Change in Net Operating Assets | -108.79% | -0.08% | 268.82% | -426.35% | 155.17% |
| Cash from Operations | -22.51% | 229.44% | 87.87% | -336.11% | -142.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 73.86% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 1,909.79% | -68.58% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -99.83% | 100.00% | -100.00% | -28.60% |
| Cash from Financing | 316.23% | -13.81% | 217.34% | 109.49% | -108.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.19% | 171,275.00% | 114.32% | 23.41% | -120.87% |